用efgartigimod治疗耐药免疫媒介性死性肌肉病变的治疗方法
MengTing Yang1, JingChu Yuan1, YiKang Wang1
1Department of Neurology, Peking University First Hospital, Beijing, China.
Frontiers in immunology
|November 6, 2024
概括
埃夫加蒂格莫德在通过降低免疫球蛋白G水平来治疗耐药免疫媒介性死肌病 (IMNM) 方面表现有前途. 这种疗法可以帮助缩短疾病的持续时间,并尽量减少IMNM患者的慢性肌病特征.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫媒介性死性肌肉病变 (IMNM) 是一种罕见的,严重的自身免疫性疾病,其特征是肌肉软弱.
- 耐药性IMNM病例通常预后不佳,治疗选择有限.
- 向免疫球蛋白G (IgG) 降解是对自身免疫性疾病的一种潜在治疗策略.
研究的目的:
- 评估efgartigimod在耐火性IMNM患者中的疗效和安全性.
- 为了评估临床反应,自抗体水平的变化和efgartigimod治疗后的不良事件.
主要方法:
- 一项开放式试点观察性研究,涉及7名耐火性IMNM患者.
- 静脉注射efgartigimod的使用.
- 使用已确定的标准进行临床反应评估,并测量血清IgG和特定自身抗体 (抗SRP,抗HMGCR).
主要成果:
- 在七名患者中,有四名患者获得了对efgartigimod.com的临床反应.
- 在治疗后观察到血清IgG和抗HMGCR/SRP抗体水平的显著降低.
- 与响应者相比,非响应者在肌肉活检上表现出更长的疾病持续时间和更多的慢性肌病特征.
- 一名患者报告了轻微的不良事件 (头痛).
结论:
- 通过促进IgG降解,Efgartigimod在治疗耐火性IMNM方面显示出潜在的有效性.
- 这种药物可能为耐火性IMNM提供一种新的治疗途径,有可能改善结果并减少疾病的慢性化.
- 需要对更大的队列进行进一步的研究来证实这些发现.
更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.3K
09:17Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis
Published on: August 24, 2017
7.7K
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
01:14Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
01:15Myasthenia Gravis: Diagnostic Tests
661
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
661